Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia

被引：14
|
作者：
Shukla, Neerav [1 ]
Sulis, Maria Luisa [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Pediat, 1275 York Ave, New York, NY 10021 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2021年 / 325卷 / 09期
关键词：
D O I：
10.1001/jama.2021.1395
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：830 / 832
页数：3
相关论文
共 50 条
  • [1] Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia
    J. L. Fuster
    F. Bautista
    B. González
    J. M. Fernández
    S. Rives
    J. L. Dapena
    Clinical and Translational Oncology, 2021, 23 : 1963 - 1966
  • [2] Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia
    Fuster, J. L.
    Bautista, F.
    Gonzalez, B.
    Fernandez, J. M.
    Rives, S.
    Dapena, J. L.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (09): : 1963 - 1966
  • [3] Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Anthony Stein
    Janet L. Franklin
    Victoria M. Chia
    Deborah Arrindell
    William Kormany
    Jacqueline Wright
    Mandy Parson
    Hamid R. Amouzadeh
    Jessica Choudhry
    Guiandre Joseph
    Drug Safety, 2019, 42 : 587 - 601
  • [4] Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Stein, Anthony
    Franklin, Janet L.
    Chia, Victoria M.
    Arrindell, Deborah
    Kormany, William
    Wright, Jacqueline
    Parson, Mandy
    Amouzadeh, Hamid R.
    Choudhry, Jessica
    Joseph, Guiandre
    DRUG SAFETY, 2019, 42 (05) : 587 - 601
  • [5] Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab
    Wudhikarn, Kitsada
    King, Amber C.
    Geyer, Mark B.
    Roshal, Mikhail
    Bernal, Yvette
    Gyurkocza, Boglarka
    Perales, Miguel-Angel
    Park, Jae H.
    BLOOD ADVANCES, 2022, 6 (05) : 1432 - 1443
  • [6] The Usefulness of Blinatumomab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Review
    Watakabe, Mai
    Arakawa, Yuki
    Irikura, Tomoya
    Honda, Mamoru
    Mitani, Yuichi
    Oshima, Koichi
    Watanabe, Atsuko
    Mori, Makiko
    Fukuoka, Kohei
    Koh, Katsuyoshi
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [7] Targeting osteoclasts for treatment of high-risk B-cell acute lymphoblastic leukemia
    Kotecha, Rishi S.
    Trinder, Sarah M.
    Hughes, Anastasia M.
    Mullin, Benjamin H.
    Rashid, Sarah
    Yuan, Jinbo
    Xu, Jiake
    Duncan, Owen
    Skut, Patrycja
    Chua, Grace-Alyssa
    Singh, Sajla
    Oommen, Joyce
    Lock, Richard B.
    Kees, Ursula R.
    Malinge, Sebastien
    Kuek, Vincent
    Cheung, Laurence C.
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [8] FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia
    Pulte, E. Dianne
    Vallejo, Jonathon
    Przepiorka, Donna
    Nie, Lei
    Farrell, Ann T.
    Goldberg, Kirsten B.
    McKee, Amy E.
    Pazdur, Richard
    ONCOLOGIST, 2018, 23 (11): : 1366 - 1371
  • [9] Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Goekbuget, Nicola
    Kantarjian, Hagop M.
    Brueggemann, Monika
    Stein, Anthony S.
    Bargou, Ralf C.
    Dombret, Herve
    Fielding, Adele K.
    Heffner, Leonard
    Rigal-Huguet, Francoise
    Litzow, Mark
    O'Brien, Susan
    Zugmaier, Gerhard
    Gao, Shan
    Nagorsen, Dirk
    Forman, Stephen J.
    Topp, Max S.
    BLOOD ADVANCES, 2019, 3 (20) : 3033 - 3037
  • [10] Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab
    Queudeville, Manon
    Handgretinger, Rupert
    Ebinger, Martin
    ONCOTARGETS AND THERAPY, 2017, 10 : 3567 - 3578
12345